The proxy fight is settled, removing near-term overhang. Watch for the identity and background of the mutually agreed New Director within 90 days post-meeting, a credible independent biotech operator would signal continued governance improvement. The standstill and vote-support agreement ensure a clean annual meeting result on July 16, after which the share price catalyst shifts back to clinical/regulatory milestones for Vaxart's oral vaccine platform.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jul 6 $0.6200entry
- T+1 · 4mo ago −11.24%α −10.77% · $0.5503
- T+5 · 4mo ago −13.84%α −13.56% · $0.5342
- T+20 · 4mo ago −4.84%α −5.69% · $0.5900
- T+60 · 7w ago −26.77%α −28.93% · $0.4540
Price Chart
How similar events traded
Executive Summary
Vaxart and the Houle Stockholder Group entered into a Cooperation Agreement on July 1, 2026, ending the proxy contest for the July 16 annual meeting. The dissidents withdrew their three director nominations and books-and-records demand, and the board will adopt governance changes including a majority-vote resignation policy, stock ownership guidelines, new board committees, and a process to mutually appoint one independent director. The board's six nominees are now unopposed and the annual meeting vote is de-escalated to routine status.
Key Financial Metrics
Key Facts
- Cooperation Agreement signed July 1, 2026 between Vaxart and Daniel P. Houle's Stockholder Group (Houle, Silverberg, Wallace, Raffy, Q3 Nominees, Pereira).
- Dissidents withdrew all three director nominations and their books-and-records demand.
- Within 60-90 days post-meeting, board will mutually agree with the Stockholder Group on one independent director (the 'New Director').
- Board commits to adopt a resignation policy for directors receiving < majority votes in uncontested elections, directors' stock ownership guidelines, a Clinical and Regulatory Affairs Committee chaired by James Breitmeyer, a Stockholder Engagement Committee chaired by the New Director, and new committee chairs for NCG and Compensation.
- Stockholder Group agreed to vote its shares in line with the board's recommendations and is subject to standstill and non-disparagement provisions.
- Vaxart will reimburse up to $650,000 of the Stockholder Group's out-of-pocket expenses related to the proxy contest.
- Previously submitted WHITE proxy cards remain valid, but votes for the three withdrawn dissident nominees will be disregarded.
- Annual meeting remains July 16, 2026, record date unchanged at May 26, 2026.
Financial Impact
Vaxart agrees to reimburse up to $650,000 in expenses to the Stockholder Group; no other financial terms disclosed.
Risk Factors
- If the 60-90 day process to appoint the New Director stalls or produces a weak candidate, the governance improvements may be viewed as cosmetic.
- The standstill and non-disparagement provisions limit near-term activist pressure, removing a potential catalyst for operational change.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (VXRT), Batch item 1 | 0001213900-26-075169 |
| Document: 0001213900-26-075169-index-headers.html | 0001213900-26-075169 |
| Document: 0001213900-26-075169-index.html | 0001213900-26-075169 |
| Document: 0001213900-26-075169.txt | 0001213900-26-075169 |
| DEFA14A Filing (VXRT), Batch item 5 | 0001213900-26-075169 |
| Document: 0001213900-26-075169-index-headers.html | 0001213900-26-075169 |
| Document: 0001213900-26-075169-index.html | 0001213900-26-075169 |
| Document: 0001213900-26-075169.txt | 0001213900-26-075169 |
Track record
23 reports on VXRT
2 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +37.66% at T+60 after the May 1, 2026 report. 2 of 4 went positive at some point.
Filters
- Nov 5, 202611d ago 8-K Bearish 5/10 Entry $0.3700 Now $0.3600 +2.70% settles Feb 4
- Oct 19, 202628d ago 8-K Neutral 3/10 Entry $0.4900 Now $0.3600 −26.53% settles Jan 15
- Jul 28, 202615w ago 8-K Neutral 2/10 Entry $0.4800 to $0.4900 Now $0.3600 −25.00% ▲ +2.08% −2.53% vs SPY
- Jul 7, 202618w ago 8-K Neutral 4/10 Entry $0.5500 to $0.4500 Now $0.3600 −34.55% ▼ −18.18% −21.27% vs SPY
- Jul 6, 202619w ago DEFA14A Neutral 5/10 Viewing Entry $0.6200 to $0.4540 Now $0.3600 −41.94% ▼ −26.77% −28.93% vs SPY
- Jul 2, 202619w ago DEFA14A Bullish 5/10 Entry $0.6400 to $0.4500 Now $0.3600 −43.75% ▼ −29.69% −33.51% vs SPY
- Jul 2, 202619w ago 8-K Neutral 4/10 Entry $0.6400 to $0.4520 Now $0.3600 −43.75% ▼ −29.38% −32.80% vs SPY
- Jun 26, 202620w ago DEFA14A Neutral 4/10 Entry $0.5700 to $0.4900 Now $0.3600 −36.84% ▼ −14.04% −17.08% vs SPY
- Jun 26, 202620w ago DEFA14A Neutral 3/10 Entry $0.5700 to $0.4900 Now $0.3600 −36.84% ▼ −14.04% −17.08% vs SPY
- Jun 26, 202620w ago 8-K Mixed 5/10 Entry $0.5700 to $0.4900 Now $0.3600 −36.84% ▼ −14.04% −17.08% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers